Study on the Development of the Mechanism of Action, Prevention and Treatment for Irinotecan-induced Diarrhea

Abstract

Abstract: ObjectiveTo review the mechanism of irinotecan-induced type diarrhea and the prevention and therapy for it. MethodsAnalyze the irinotecan-induced diarrhea based on the relevance literature searched on the PUBMED and CNKI from 2001 to 2011. ResultsMetabolic processes of irinotecan is affected by a variety of metabolic enzymes, genes and proteins. Many drugs have different therapeutic effects for the delayed diarrhea. Conlusion Make an in-depth understanding of the mechanism of irinotecan-induced delayed diarrhea, which can further improve its safety and efficacy.

Key words: irinotecan, diarrhea, UGT1A1, prevention and treatment

ZHANG Xiao-guang, ZHANG Xia. Study on the Development of the Mechanism of Action, Prevention and Treatment for Irinotecan-induced Diarrhea[J]. Chinese Journal of Pharmacovigilance, 2012, 9(9): 535-538.

References

[1] Zhou Y,Gwadry F G,Reinhold W C,et al.Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage:microarray analysis of dose and time-dependent effects[J].Cancer Res,2002,62(6):1688-95.
[2] 孙华君,王翠松.伊立替康肠毒性预防研究进展[J].世界临床药物,2005,26(5):286-291.
[3] Stein A,Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management[J]. Ther Adv Med Oncol. 2010,2(1):51-63.
[4] Hicks LD,Hyatt J L,Stoddard S,et al.Improved,se-lective,human intestinal carboxylesterase inhibitors designed to nodulate 7-ethyl-
10-[4-(1-p iperidino)-1-piperidino] carbonyloxy-camp tothecin
5 (irinotecan; CPT-11) toxicity[J]. M ed Chem, 2009, 52(12): 3742-
6 3752.
[5] Jessica M. van der Bol, Ron H.J Mathijssen, Geert-Jan M. Creemers,et al.A CYP3A4 Phenotype-Based Dosing Algorithm for Individ-
ualized Treatment of Irinotecan [J]. Clin Cancer Res,2010,2(16)：736.
[6] Andrea M. Stringer ,Rachel J. Gibson ,Richard M,et al.Irinotecan-induced mucositis is associated with changes in intestinal mucins[J] .Cancer Chemother Pharmacol ,2009,64:123-132.
[7] Stringer A M,Gibson R J,Logann R M,et al. Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat[J].Exp Biol MedJanuary ,2007,;232(1):96-106.
[8] Antonello Di Paolo,Guido Bocci,Marialuisa Polillo,et al. Pharmacokinetic and Pharmacogenetic Predictive Markers of Irinotecan Activity and Toxicity[J]. Current Drug Metabolism, 2011, 12: 932-943.
[9] Cecchin E,Innocenti F,D'Andrea M,et al.Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan[J].Clin. Oncol,2009, 27(15):2457-2465.
[10] Ando, Y, Saka, H, Asai, G, et al. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan[J].Ann. Oncol., 1998, 9(8):845-847.